{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-049300","form_type":"8-K","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2023-06-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.143980+00:00","generated_at":"2026-06-13T23:44:54.939250+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ABVC BioPharma appoints Dr. T.S. Jiang as CSO after Dr. King resigns","bullets":["Dr. Richard King resigned as Chief Scientific Officer effective June 13, 2023.","Resignation not due to any disagreement with company operations, policies, or practices.","Board appointed Dr. Tsung-Shann (T.S.) Jiang, current Chief Strategy Officer and director, as replacement CSO."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-049300","json":"https://secwatch.observer/filing/0001213900-23-049300.json","markdown":"https://secwatch.observer/filing/0001213900-23-049300.md","text":"https://secwatch.observer/filing/0001213900-23-049300.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023049300/0001213900-23-049300-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023049300/ea180383-8k_abvcbiopharm.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T23:44:54.939250+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6fe8d529ae","claim":"Dr. Richard King resigned as Chief Scientific Officer at ABVC BIOPHARMA, INC..","evidence_excerpt":"Dr. Richard King, the Company’s Chief Scientific Officer (“CSO”) of ABVC BioPharma, Inc. (the “Company”), notified the Company of his resignation, effective June 13, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023049300/0001213900-23-049300-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"d5098d49a0","claim":"Dr. Tsung-Shann (T.S.) Jiang was appointed as Chief Scientific Officer at ABVC BIOPHARMA, INC..","evidence_excerpt":"The Company’s board of directors appointed Dr. Tsung-Shann (T.S.) Jiang to replace Dr. King as the Company’s CSO.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023049300/0001213900-23-049300-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}